Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 May;36(5):907–912. doi: 10.1128/aac.36.5.907

In vivo antibiotic synergism: contribution of animal models.

B Fantin 1, C Carbon 1
PMCID: PMC188745  PMID: 1510412

Full text

PDF
907

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer G., Fekety F. R., Jr Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. J Infect Dis. 1977 Sep;136(3):327–335. doi: 10.1093/infdis/136.3.327. [DOI] [PubMed] [Google Scholar]
  2. Bamberger D. M., Peterson L. R., Gerding D. N., Moody J. A., Fasching C. E. Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. J Antimicrob Chemother. 1986 Jul;18(1):51–63. doi: 10.1093/jac/18.1.51. [DOI] [PubMed] [Google Scholar]
  3. Bartlett J. G., Louie T. J., Gorbach S. L., Onderdonk A. B. Therapeutic efficacy of 29 antimicrobial regimens in experimental intraabdominal sepsis. Rev Infect Dis. 1981 May-Jun;3(3):535–542. doi: 10.1093/clinids/3.3.535. [DOI] [PubMed] [Google Scholar]
  4. Bayer A. S., Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985 Jan;151(1):157–165. doi: 10.1093/infdis/151.1.157. [DOI] [PubMed] [Google Scholar]
  5. Bayer A. S., Norman D., Kim K. S. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1985 Dec;28(6):781–785. doi: 10.1128/aac.28.6.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bush L. M., Calmon J., Cherney C. L., Wendeler M., Pitsakis P., Poupard J., Levison M. E., Johnson C. C. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann Intern Med. 1989 Apr 1;110(7):515–520. doi: 10.7326/0003-4819-110-7-515. [DOI] [PubMed] [Google Scholar]
  7. Calandra T., Glauser M. P. Immunocompromised animal models for the study of antibiotic combinations. Am J Med. 1986 May 30;80(5C):45–52. [PubMed] [Google Scholar]
  8. Caron F., Carbon C., Gutmann L. Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis. 1991 Nov;164(5):888–893. doi: 10.1093/infdis/164.5.888. [DOI] [PubMed] [Google Scholar]
  9. Caron F., Gutmann L., Bure A., Pangon B., Vallois J. M., Pechinot A., Carbon C. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase. Antimicrob Agents Chemother. 1990 Nov;34(11):2070–2074. doi: 10.1128/aac.34.11.2070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carrizosa J., Levison M. E. Minimal concentrations of aminoglycoside that can synergize with penicillin in enterococcal endocarditis. Antimicrob Agents Chemother. 1981 Sep;20(3):405–409. doi: 10.1128/aac.20.3.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chin N. X., Jules K., Neu H. C. Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection. Eur J Clin Microbiol. 1986 Feb;5(1):23–28. doi: 10.1007/BF02013456. [DOI] [PubMed] [Google Scholar]
  12. Comber K. R., Basker M. J., Osborne C. D., Sutherland R. Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob Agents Chemother. 1977 Jun;11(6):956–964. doi: 10.1128/aac.11.6.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fantin B., Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother. 1990 Dec;34(12):2387–2391. doi: 10.1128/aac.34.12.2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fantin B., Ebert S., Leggett J., Vogelman B., Craig W. A. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother. 1991 Jun;27(6):829–836. doi: 10.1093/jac/27.6.829. [DOI] [PubMed] [Google Scholar]
  15. Fantin B., Leclercq R., Arthur M., Duval J., Carbon C. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob Agents Chemother. 1991 Aug;35(8):1570–1575. doi: 10.1128/aac.35.8.1570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fantin B., Pangon B., Potel G., Caron F., Vallée E., Vallois J. M., Mohler J., Buré A., Philippon A., Carbon C. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase. Antimicrob Agents Chemother. 1990 Apr;34(4):581–586. doi: 10.1128/aac.34.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fantin B., Pangon B., Potel G., Vallois J. M., Caron F., Bure A., Carbon C. Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis. Antimicrob Agents Chemother. 1989 May;33(5):767–770. doi: 10.1128/aac.33.5.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Franciolli M., Bille J., Glauser M. P., Moreillon P. Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis. 1991 Mar;163(3):514–523. doi: 10.1093/infdis/163.3.514. [DOI] [PubMed] [Google Scholar]
  19. Galetto D. W., Boscia J. A., Kobasa W. D., Kaye D. Teicoplanin compared with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J Infect Dis. 1986 Jul;154(1):69–75. doi: 10.1093/infdis/154.1.69. [DOI] [PubMed] [Google Scholar]
  20. Glauser M. P., Bonard Treatment of experimental ascending Escherichia coli pyelonephritis with ceftriaxone alone and in combination with gentamicin. Chemotherapy. 1982;28(5):410–416. doi: 10.1159/000238130. [DOI] [PubMed] [Google Scholar]
  21. Glauser M. P., Lyons J. M., Braude A. I. Synergism of ampicillin and gentamicin against obstructive pyelonephritis due to Escherichia coli in rats. J Infect Dis. 1979 Feb;139(2):133–140. doi: 10.1093/infdis/139.2.133. [DOI] [PubMed] [Google Scholar]
  22. Haller I. Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains. Antimicrob Agents Chemother. 1985 Nov;28(5):663–666. doi: 10.1128/aac.28.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Henry N. K., Rouse M. S., Whitesell A. L., McConnell M. E., Wilson W. R. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med. 1987 Apr 27;82(4A):73–75. [PubMed] [Google Scholar]
  24. Henry N. K., Wilson W. R., Geraci J. E. Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low- or high-dose streptomycin. Antimicrob Agents Chemother. 1986 Nov;30(5):725–728. doi: 10.1128/aac.30.5.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hessen M. T., Pitsakis P. G., Levison M. E. Postantibiotic effect of penicillin plus gentamicin versus Enterococcus faecalis in vitro and in vivo. Antimicrob Agents Chemother. 1989 May;33(5):608–611. doi: 10.1128/aac.33.5.608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ingerman M., Pitsakis P. G., Rosenberg A., Hessen M. T., Abrutyn E., Murray B. E., Levison M. E. beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis. 1987 Jun;155(6):1226–1232. doi: 10.1093/infdis/155.6.1226. [DOI] [PubMed] [Google Scholar]
  27. Kaatz G. W., Seo S. M., Barriere S. L., Albrecht L. M., Rybak M. J. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989 Aug;33(8):1184–1187. doi: 10.1128/aac.33.8.1184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kapusnik J. E., Hackbarth C. J., Chambers H. F., Carpenter T., Sande M. A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul;158(1):7–12. doi: 10.1093/infdis/158.1.7. [DOI] [PubMed] [Google Scholar]
  29. Kapusnik J. E., Sande M. A. Challenging conventional aminoglycoside dosing regimens. The value of experimental models. Am J Med. 1986 Jun 30;80(6B):179–181. doi: 10.1016/0002-9343(86)90498-5. [DOI] [PubMed] [Google Scholar]
  30. Kobasa W. D., Kaye D. Aztreonam, cefoperazone, and gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis in rabbits. Antimicrob Agents Chemother. 1983 Sep;24(3):321–324. doi: 10.1128/aac.24.3.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Korzeniowski O. M., Wennersten C., Moellering R. C., Jr, Sande M. A. Penicillin-netilmicin synergism against Streptococcus faecalis. Antimicrob Agents Chemother. 1978 Mar;13(3):430–434. doi: 10.1128/aac.13.3.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Levison M. E., Kobasa W. D. Mezlocillin and ticarcillin alone and combined with gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis. Antimicrob Agents Chemother. 1984 Jun;25(6):683–686. doi: 10.1128/aac.25.6.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lucet J. C., Herrmann M., Rohner P., Auckenthaler R., Waldvogel F. A., Lew D. P. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1990 Dec;34(12):2312–2317. doi: 10.1128/aac.34.12.2312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lumish R. M., Norden C. W. Therapy of neutropenic rats infected with Pseudomonas aeruginosa. J Infect Dis. 1976 May;133(5):538–547. doi: 10.1093/infdis/133.5.538. [DOI] [PubMed] [Google Scholar]
  35. Matsumoto J. Y., Wilson W. R., Wright A. J., Geraci J. E., Washington J. A., 2nd Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob Agents Chemother. 1980 Dec;18(6):944–947. doi: 10.1128/aac.18.6.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Michéa-Hamzehpour M., Auckenthaler R., Regamey P., Pechère J. C. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother. 1987 Nov;31(11):1803–1808. doi: 10.1128/aac.31.11.1803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Michéa-Hamzehpour M., Pechère J. C., Marchou B., Auckenthaler R. Combination therapy: a way to limit emergence of resistance? Am J Med. 1986 Jun 30;80(6B):138–142. doi: 10.1016/0002-9343(86)90491-2. [DOI] [PubMed] [Google Scholar]
  38. Moody J. A., Gerding D. N., Peterson L. R. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. Am J Med. 1987 Apr 27;82(4A):44–54. [PubMed] [Google Scholar]
  39. Norden C. W. Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. J Infect Dis. 1975 Nov;132(5):493–499. doi: 10.1093/infdis/132.5.493. [DOI] [PubMed] [Google Scholar]
  40. Norden C. W. Experimental osteomyelitis. V. Therapeutic trials with oxacillin and sisomicin alone and in combination. J Infect Dis. 1978 Feb;137(2):155–160. doi: 10.1093/infdis/137.2.155. [DOI] [PubMed] [Google Scholar]
  41. Norden C. W., Keleti E. Experimental osteomyelitis caused by Pseudomonas aeruginosa. J Infect Dis. 1980 Jan;141(1):71–75. doi: 10.1093/infdis/141.1.71. [DOI] [PubMed] [Google Scholar]
  42. Norden C. W., Shaffer M. Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin. J Infect Dis. 1983 Feb;147(2):352–357. doi: 10.1093/infdis/147.2.352. [DOI] [PubMed] [Google Scholar]
  43. Pechère J. C., Marchou B., Michéa-Hamzehpour M., Auckenthaler R. Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother. 1986 Mar;17 (Suppl A):11–18. doi: 10.1093/jac/17.suppl_a.11. [DOI] [PubMed] [Google Scholar]
  44. Pennington J. E., Stone R. M. Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis. 1979 Dec;140(6):881–889. doi: 10.1093/infdis/140.6.881. [DOI] [PubMed] [Google Scholar]
  45. Rusnak M. G., Drake T. A., Hackbarth C. J., Sande M. A. Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs. J Infect Dis. 1984 Jun;149(6):980–985. doi: 10.1093/infdis/149.6.980. [DOI] [PubMed] [Google Scholar]
  46. Sande M. A., Courtney K. B. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J Lab Clin Med. 1976 Jul;88(1):118–124. [PubMed] [Google Scholar]
  47. Sande M. A., Irvin R. G. Penicillin-aminoglycoside synergy in experimental Streptococcus viridans endocarditis. J Infect Dis. 1974 May;129(5):572–576. doi: 10.1093/infdis/129.5.572. [DOI] [PubMed] [Google Scholar]
  48. Scheld W. M., Fletcher D. D., Fink F. N., Sande M. A. Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes. J Infect Dis. 1979 Sep;140(3):287–294. doi: 10.1093/infdis/140.3.287. [DOI] [PubMed] [Google Scholar]
  49. Scott R. E., Robson H. G. Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats. Antimicrob Agents Chemother. 1976 Oct;10(4):646–651. doi: 10.1128/aac.10.4.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Thauvin C., Lemeland J. F., Humbert G., Fillastre J. P. Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1988 Jun;32(6):919–921. doi: 10.1128/aac.32.6.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W. A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988 Oct;158(4):831–847. doi: 10.1093/infdis/158.4.831. [DOI] [PubMed] [Google Scholar]
  52. Vogelman B., Gudmundsson S., Turnidge J., Leggett J., Craig W. A. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988 Feb;157(2):287–298. doi: 10.1093/infdis/157.2.287. [DOI] [PubMed] [Google Scholar]
  53. Washburn R. G., Durack D. T. Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus. J Infect Dis. 1981 Sep;144(3):237–243. doi: 10.1093/infdis/144.3.237. [DOI] [PubMed] [Google Scholar]
  54. Weinstein W. M., Onderdonk A. B., Bartlett J. G., Louie T. J., Gorbach S. L. Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis. 1975 Sep;132(3):282–286. doi: 10.1093/infdis/132.3.282. [DOI] [PubMed] [Google Scholar]
  55. Wilson W. R., Zak O., Sande M. A. Penicillin therapy for treatment of experimental endocarditis caused by viridans streptococci in animals. J Infect Dis. 1985 Jun;151(6):1028–1033. doi: 10.1093/infdis/151.6.1028. [DOI] [PubMed] [Google Scholar]
  56. Wright A. J., Wilson W. R., Matsumoto J. Y., Washington J. A., 2nd, Geraci J. E. Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis. Antimicrob Agents Chemother. 1982 Dec;22(6):972–975. doi: 10.1128/aac.22.6.972. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES